Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone
(2024)
Journal Article
Kundu, J., Le, H. T., Logan, M., Hockman, D., Landi, A., Crawford, K., Wininger, M., Johnson, J., Kundu, J. K., Tiffney, E. A., Urbanowicz, R. A., Ball, J. K., Bailey, J. R., Bukh, J., Law, M., Foung, S., Tyrrell, D. L., Houghton, M., & Law, J. L. (in press). Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone. Journal of Hepatology, https://doi.org/10.1016/j.jhep.2024.06.029
Background & Aims
An optimal HCV vaccine requires the induction of antibodies that neutralise the infectivity of many heterogenous viral isolates. In this study, we have focused on determining the optimal recombin...
Read More about Recombinant H77C gpE1/gpE2 heterodimer elicits superior HCV cross-neutralisation than H77C gpE2 alone.